KR100704168B1 - 갈근에서 분리되는 당뇨합병증 치료 또는 예방용 화합물 및그 분리방법 - Google Patents
갈근에서 분리되는 당뇨합병증 치료 또는 예방용 화합물 및그 분리방법 Download PDFInfo
- Publication number
- KR100704168B1 KR100704168B1 KR1020060035464A KR20060035464A KR100704168B1 KR 100704168 B1 KR100704168 B1 KR 100704168B1 KR 1020060035464 A KR1020060035464 A KR 1020060035464A KR 20060035464 A KR20060035464 A KR 20060035464A KR 100704168 B1 KR100704168 B1 KR 100704168B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- active ingredient
- diabetic complications
- preventing
- structural formula
- Prior art date
Links
- 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 31
- 206010012655 Diabetic complications Diseases 0.000 title claims abstract description 29
- 230000002265 prevention Effects 0.000 title claims description 11
- 238000000926 separation method Methods 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 229940045109 genistein Drugs 0.000 claims abstract description 22
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000006539 genistein Nutrition 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 14
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 9
- -1 furan compound Chemical class 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000003712 anti-aging effect Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- WDOIEKGCNWFDSA-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-1-benzofuran-3-carbaldehyde Chemical class COC1=CC(O)=CC=C1C1=C(C=O)C2=CC=C(O)C=C2O1 WDOIEKGCNWFDSA-UHFFFAOYSA-N 0.000 abstract description 52
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 abstract description 21
- 238000004519 manufacturing process Methods 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 16
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- 230000036252 glycation Effects 0.000 description 15
- 229940125904 compound 1 Drugs 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000000401 methanolic extract Substances 0.000 description 8
- 102000016912 Aldehyde Reductase Human genes 0.000 description 7
- 108010053754 Aldehyde reductase Proteins 0.000 description 7
- 229930091371 Fructose Natural products 0.000 description 7
- 239000005715 Fructose Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229920005862 polyol Polymers 0.000 description 5
- 150000003077 polyols Chemical class 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010007749 Cataract diabetic Diseases 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- 244000046146 Pueraria lobata Species 0.000 description 4
- 235000010575 Pueraria lobata Nutrition 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 4
- 201000007025 diabetic cataract Diseases 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 241000219780 Pueraria Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005100 correlation spectroscopy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 108010004903 glycosylated serum albumin Proteins 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000004791 1D NOESY Methods 0.000 description 1
- YVDMDAVAAHHPDH-UHFFFAOYSA-N 2-aminoguanidine Chemical compound NNC(N)=N.NNC(N)=N YVDMDAVAAHHPDH-UHFFFAOYSA-N 0.000 description 1
- SVVGZXKQDCEBAU-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxy-2,5-dimethoxyphenyl)-1-benzofuran-3-carbaldehyde Chemical compound COc1cc(-c2oc3cc(O)ccc3c2C=O)c(OC)cc1O SVVGZXKQDCEBAU-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 238000010260 bioassay-guided fractionation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002518 distortionless enhancement with polarization transfer Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 150000002232 fructoses Chemical class 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
화합물\효능 | ㎍ /mL | 억제효능 | 억제효능(IC50 값) (㎍/mL) | 억제효능(IC50 값) (μM) |
푸에라리아푸란(1) (3-포밀-2-(4-하이드로옥시-2-메톡시페닐)-6-하이드로벤조퓨란) | 0.05 | 4.88±1.42 | 0.15 | 0.53 |
0.1 | 22.03±2.41 | |||
0.2 | 71.84±1.88 | |||
쿠메스테롤(2) | 0.01 | 18.52±6.58 | 0.05 | 0.19 |
0.025 | 27.78±3.07 | |||
0.05 | 50.48±3.76 | |||
다이드제인(3) | 5 | 25.06±1.86 | 12.0 | 47.2 |
10 | 44.81±2.80 | |||
25 | 94.20±2.88 | |||
제니스테인(4) | 65 | 48.21±1.31 | 70.1 | 260 |
80 | 53.51±0.89 | |||
95 | 58.51±1.73 | |||
아미노구아니딘 Aminoguanidine | 9.25 | 25.29±3.22 | 34.56 | 473 |
18.5 | 54.63±0.88 | |||
37 | 69.69±0.88 |
Claims (18)
- 갈근을 수용액, 수용성 알콜 또는 유기용매 중 선택되는 용매로 추출한 후 농축시켜 추출물을 얻는 단계와;상기 추출물을 크로마토그래피를 반복 실시하여 2-아릴벤조푸란 유도체를 얻는 단계로 이루어지는 것을 특징으로 하는 갈근에서 분리되는 푸에라리아푸란 화합물의 분리방법.
- 제 2항의 구조식 1로 표시되는 푸에라리아푸란 화합물 또는 2-아릴벤조푸란 유도체를 유효성분으로 함유하는 당뇨합병증 예방 또는 치료를 위한 약학조성물.
- 제 2항의 구조식 1로 표시되는 푸에라리아푸란 화합물 또는 2-아릴벤조푸란 유도체를 유효성분으로 함유하는 당뇨합병증 예방 또는 치료를 위한 기능성 식품.
- 제 2항의 구조식 1로 표시되는 푸에라리아푸란 화합물 또는 2-아릴벤조푸란 유도체를 유효성분으로 함유하는 노화방지 또는 지연용 약학조성물.
- 제 2항의 구조식 1로 표시되는 푸에라리아푸란 화합물 또는 2-아릴벤조푸란 유도체를 유효성분으로 함유하는 노화방지 또는 지연용 기능성 식품.
- 제 2항의 구조식 1로 표시되는 푸에라리아푸란 화합물 또는 2-아릴벤조푸란 유도체를 유효성분으로 함유하는 항암 예방 또는 치료용 약학조성물.
- 제 2항의 구조식 1로 표시되는 푸에라리아푸란 화합물 또는 2-아릴벤조푸란 유도체를 유효성분으로 함유하는 항암 예방 또는 치료용 기능성 식품.
- 제 9항의 구조식 2로 표시되는 쿠메스테롤 화합물 또는 그 유도체를 유효성분으로 함유하는 당뇨합병증 예방 또는 치료를 위한 기능성 식품
- 제 9항의 구조식 2로 표시되는 쿠메스테롤 화합물 또는 그 유도체를 유효성분으로 함유하는 노화방지 또는 지연용 약학조성물.
- 제 9항의 구조식 2로 표시되는 쿠메스테롤 화합물 또는 그 유도체를 유효성분으로 함유하는 노화방지 또는 지연용 기능성 식품.
- 제 9항의 구조식 2로 표시되는 천연 또는 합성 쿠메스테롤 화합물 또는 그 유도체를 유효성분으로 함유하는 항암 예방 또는 치료용 약학조성물.
- 제 9항의 구조식 2로 표시되는 쿠메스테롤 화합물 또는 그 유도체를 유효성분으로 함유하는 항암 예방 또는 치료용 기능성 식품.
- 갈근에서 분리되는 다이드제인 화합물을 유효성분으로 함유하는 당뇨합병증 예방 또는 치료를 위한 약학조성물.
- 갈근에서 분리되는 다이드제인 화합물을 유효성분으로 함유하는 당뇨합병증 예방 또는 치료를 위한 기능성 식품.
- 갈근에서 분리되는 제니스테인 화합물을 유효성분으로 함유하는 당뇨합병증 예방 또는 치료를 위한 약학조성물.
- 갈근에서 분리되는 제니스테인 화합물을 유효성분으로 함유하는 당뇨합병증 예방 또는 치료를 위한 기능성 식품.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060035464A KR100704168B1 (ko) | 2006-04-19 | 2006-04-19 | 갈근에서 분리되는 당뇨합병증 치료 또는 예방용 화합물 및그 분리방법 |
PCT/KR2007/001744 WO2007119959A1 (en) | 2006-04-19 | 2007-04-11 | Composition isolated from puerariae radix for prevention or treatment of diabetic complications and a separation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060035464A KR100704168B1 (ko) | 2006-04-19 | 2006-04-19 | 갈근에서 분리되는 당뇨합병증 치료 또는 예방용 화합물 및그 분리방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100704168B1 true KR100704168B1 (ko) | 2007-04-04 |
Family
ID=38160975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060035464A KR100704168B1 (ko) | 2006-04-19 | 2006-04-19 | 갈근에서 분리되는 당뇨합병증 치료 또는 예방용 화합물 및그 분리방법 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100704168B1 (ko) |
WO (1) | WO2007119959A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106117191B (zh) * | 2016-06-22 | 2018-10-02 | 瑞安市智造科技有限公司 | 一种高效分离提纯葛根素的方法 |
-
2006
- 2006-04-19 KR KR1020060035464A patent/KR100704168B1/ko active IP Right Grant
-
2007
- 2007-04-11 WO PCT/KR2007/001744 patent/WO2007119959A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
Chem. Pharm. Bull. 54,1315-1317 |
Also Published As
Publication number | Publication date |
---|---|
WO2007119959A1 (en) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Antihyperglycemic, antioxidant activities of two Acer palmatum cultivars, and identification of phenolics profile by UPLC-QTOF-MS/MS: new natural sources of functional constituents | |
Juan-Badaturuge et al. | Antioxidant compounds from a South Asian beverage and medicinal plant, Cassia auriculata | |
Stintzing et al. | Structural investigations on betacyanin pigments by LC NMR and 2D NMR spectroscopy | |
Hwang et al. | Inhibitory activities of Stauntonia hexaphylla leaf constituents on rat lens aldose reductase and formation of advanced glycation end products and antioxidant | |
Jia et al. | Non-flavonoid phenolics from Averrhoa carambola fresh fruit | |
Waridel et al. | Identification of the polar constituents of Potamogeton species by HPLC-UV with post-column derivatization, HPLC-MSn and HPLC-NMR, and isolation of a new ent-labdane diglycoside | |
Wagner et al. | Phenylpropanes and lignans of viscum album cardioactive drugs V1 | |
MASUOKA et al. | Antioxidative, Antihyaluronidase and Antityrosinase Activities of Some Constituents from the Aerial Part of Piper elongatum VAHL. | |
Lee et al. | 2 ″, 4 ″-O-diacetylquercitrin, a novel advanced glycation end-product formation and aldose reductase inhibitor from Melastoma sanguineum | |
Lee et al. | Flavonoids from Litsea japonica inhibit AGEs formation and rat lense aldose reductase in vitro and vessel dilation in zebrafish | |
Kulesh et al. | Antioxidant activity of the isoflavonoids from the roots of Maackia amurensis | |
Zhang et al. | New dimeric and trimeric Erythrina alkaloids from Erythrina variegata | |
Barakat et al. | Flavonoid galloyl glucosides from the pods of Acaciafarnesiana | |
Ha et al. | Isolation and identification of α-glucosidase inhibitory constituents from the seeds of vigna nakashimae: Enzyme kinetic study with active phytochemical | |
Soltani et al. | New Specific α‐Glucosidase Inhibitor Flavonoid from Thymelaea tartonraira Leaves: Structure Elucidation, Biological and Molecular Docking Studies | |
Liu et al. | Eupafolin Rhamnosides fron Kalanchoe gracilis | |
Sgariglia et al. | Anti-inflammatory properties of phenolic lactones isolated from Caesalpinia paraguariensis stem bark | |
Simaratanamongkol et al. | Angiotensin-converting enzyme (ACE) inhibitory activity of Solanum torvum and isolation of a novel methyl salicylate glycoside | |
KR100704168B1 (ko) | 갈근에서 분리되는 당뇨합병증 치료 또는 예방용 화합물 및그 분리방법 | |
Jeong et al. | New anti-glycative flavonoids from Cirsium setidens with potent radical scavenging activities | |
EP4349845A1 (en) | Novel isoflavone compound | |
Xin-Guang et al. | New prenylated flavonoid glycosides derived from Epimedium wushanense by β-glucosidase hydrolysis and their testosterone production-promoting effects | |
Abdelhady et al. | A new sucrase enzyme inhibitor from Azadirachta indica | |
US8299119B2 (en) | Biologically active compounds | |
Muharini et al. | New flavone C-glycosides from leaves of Sarcotheca griffithii (Hook F) Hallier F |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130314 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131211 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150312 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170529 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180410 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190401 Year of fee payment: 13 |